{
  "docId": "019de072-1a15-7369-8097-68fb5b1d5017",
  "docSlug": "de0c004f3134112f269aa7aa17f1a1f3",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 39 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 39,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 17,
  "notes": "The slide uses a table format to categorize pipeline progress by regulatory status and geography.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-1a15-7369-8097-68fb5b1d5017/10",
  "deckHref": "/decks/019de072-1a15-7369-8097-68fb5b1d5017",
  "deckJsonHref": "/decks/019de072-1a15-7369-8097-68fb5b1d5017.json",
  "deckAnchorHref": "/decks/019de072-1a15-7369-8097-68fb5b1d5017#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "HER2-positive = human epidermal growth factor receptor 2 positive; BRCAm = breast cancer susceptibility gene 1/2 mutation; NSCLC = non-small cell lung cancer; NF1-PN = neurofibromatosis type 1 with plexiform neurofibromas; PNH = paroxysmal nocturnal haemoglobinuria; aHUS = atypical haemolytic uraemic syndrome. Status as of 10 February 2022.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52b9b586-5894-4b7d-9549-bf0b2e97961c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 1,
        "w": 0.3,
        "x": 0.7,
        "y": 0
      },
      "kind": "image",
      "text": "Stylized human torso silhouette with molecular/cellular overlay.",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9022895e-e63e-4034-90f9-adafd9481bb2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.7,
        "x": 0.02,
        "y": 0.24
      },
      "kind": "table",
      "text": "Table listing Medicine, Indication/Event, and Geography categorized by Regulatory approvals, Submissions, and Phase III readouts.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2cb322ac-fea2-49c2-892b-ae889061b674",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Late-stage pipeline delivery",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39e3c4cf-d627-4226-8698-0dc62c552af3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "title",
      "text": "Important milestones since Q3 2021 update",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "426a10e7-4354-401e-aff0-7f74108c3e98",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 6,
      "beatId": "1ebb2b41-d88f-40eb-aa61-f0b44beb2217",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The presentation highlights the company's strong growth and pipeline, addressing the need for innovation.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 6,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "cda2daa8-5b26-4954-80bc-b7864ff91f9b",
      "evidence": "The presentation links growth to life-cycle management, pipeline, and strategic business development.",
      "position": 0,
      "objective": "How will AstraZeneca continue to drive growth?",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}